By Will Feuer
Shares of PDS Biotechnology rose about 18% after the clinical-stage company released interim data from the Phase 2 trial of its cancer drug candidate used with Merck’s Keytruda.
The stock climbed 18% to $7.94 in premarket trading. Over the past 12 months, the stock was already up almost 35% through Thursday’s close.
The company said Thursday that the trial investigating PDS0101 in combination with Keytruda yielded promising results in treating patients with with unresectable, recurrent or metastatic human papillomavirus 16-positive head and neck cancer.
“The interim data showed an estimated 12-month survival rate of 87% and a progression-free survival of 10.4 months, which is very encouraging given the poor prognosis these patients face,” said PDS Biotechnology Chief Medical Officer Lauren Wood.
Write to Will Feuer at Will.Feuer@wsj.com
Read the full article here
